• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).

作者信息

Furst D E, Breedveld F C, Kalden J R, Smolen J S, Antoni C E, Bijlsma J W J, Burmester G R, Cronstein B, Keystone E C, Kavanaugh A, Klareskog L

机构信息

University of California, Los Angeles, CA, USA.

出版信息

Ann Rheum Dis. 2002 Nov;61 Suppl 2(Suppl 2):ii2-7. doi: 10.1136/ard.61.suppl_2.ii2.

DOI:10.1136/ard.61.suppl_2.ii2
PMID:12379612
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1766714/
Abstract
摘要

相似文献

1
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).关于治疗类风湿关节炎及其他风湿性疾病的生物制剂的最新共识声明（2002年5月）
Ann Rheum Dis. 2002 Nov;61 Suppl 2(Suppl 2):ii2-7. doi: 10.1136/ard.61.suppl_2.ii2.
2
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.《2008年关于治疗风湿性疾病生物制剂的更新共识声明》
Ann Rheum Dis. 2008 Dec;67 Suppl 3:iii2-25. doi: 10.1136/ard.2008.100834.
3
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.《2007年关于治疗风湿性疾病生物制剂的更新共识声明》
Ann Rheum Dis. 2007 Nov;66 Suppl 3(Suppl 3):iii2-22. doi: 10.1136/ard.2007.081430.
4
The use of biological therapy in refractory rheumatic diseases other than rheumatoid arthritis: experience at a tertiary care center in Lebanon.生物疗法在类风湿关节炎以外的难治性风湿性疾病中的应用：黎巴嫩一家三级医疗中心的经验。
Rheumatol Int. 2009 Aug;29(10):1255-7. doi: 10.1007/s00296-008-0816-0. Epub 2008 Dec 4.
5
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.《2005年关于生物制剂，特别是肿瘤坏死因子α（TNFα）阻断剂和白细胞介素-1受体拮抗剂（IL-1ra）治疗风湿性疾病的更新共识声明》
Ann Rheum Dis. 2005 Nov;64 Suppl 4(Suppl 4):iv2-14. doi: 10.1136/ard.2005.044941.
6
Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001).关于肿瘤坏死因子阻断剂治疗类风湿关节炎和其他风湿性疾病的最新共识声明（2001年4月）
Ann Rheum Dis. 2001 Nov;60 Suppl 3(Suppl 3):iii2-5. doi: 10.1136/ard.60.90003.iii2.
7
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.《2006年关于治疗风湿性疾病生物制剂的最新共识声明》
Ann Rheum Dis. 2006 Nov;65 Suppl 3(Suppl 3):iii2-15. doi: 10.1136/ard.2006.061937.
8
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011.《2011年关于治疗风湿性疾病生物制剂的更新共识声明》
Ann Rheum Dis. 2012 Apr;71 Suppl 2:i2-45. doi: 10.1136/annrheumdis-2011-201036.
9
Future use of biologic agents alone and in combination for the treatment of rheumatoid arthritis.生物制剂单独及联合用于类风湿关节炎治疗的未来应用。
Z Rheumatol. 1998 Feb;57(1):41-5. doi: 10.1007/s003930050058.
10
Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000).关于肿瘤坏死因子阻断剂治疗类风湿关节炎的更新共识声明（2000年5月）
Ann Rheum Dis. 2000 Nov;59 Suppl 1(Suppl 1):i1-2. doi: 10.1136/ard.59.suppl_1.i1.

引用本文的文献

1
The Derivative of Hook F-Kunxian Capsule, Attenuated Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.胡坤仙胶囊衍生物治疗类风湿关节炎：一项系统评价与Meta分析
Evid Based Complement Alternat Med. 2020 Aug 12;2020:4178140. doi: 10.1155/2020/4178140. eCollection 2020.
2
Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study.意大利三个风湿病科日常实践中的生物疗法与感染：一项前瞻性观察研究。
Clin Rheumatol. 2017 Feb;36(2):251-260. doi: 10.1007/s10067-016-3444-1. Epub 2016 Oct 25.
3
Ultrasound Detection of Salmonella Septic Arthritis in a Rheumatoid Arthritis Patient on Anti-TNF Treatment.超声检测抗TNF治疗的类风湿关节炎患者的沙门氏菌感染性关节炎
J Investig Med High Impact Case Rep. 2014 Apr 17;2(2):2324709614532799. doi: 10.1177/2324709614532799. eCollection 2014 Apr-Jun.
4
A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis.一项前瞻性、随机、双盲、多中心、平行组、活性药物对照研究，比较生物类似药阿达木单抗（逸善能；ZRC-3197）和阿达木单抗（修美乐）在类风湿性关节炎患者中的疗效和安全性。
Int J Rheum Dis. 2016 Nov;19(11):1157-1168. doi: 10.1111/1756-185X.12711. Epub 2015 Jul 14.
5
Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial.影像学损伤程度和影像学进展是身体功能的决定因素：TEMPO试验的纵向分析。
Ann Rheum Dis. 2008 Sep;67(9):1267-70. doi: 10.1136/ard.2007.081331. Epub 2008 Jan 18.
6
Etanercept in the treatment of rheumatoid arthritis: clinical follow-up over one year by ultrasonography.依那西普治疗类风湿关节炎：一年超声临床随访
Clin Rheumatol. 2008 Apr;27(4):491-6. doi: 10.1007/s10067-007-0738-3. Epub 2007 Oct 19.
7
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.《2007年关于治疗风湿性疾病生物制剂的更新共识声明》
Ann Rheum Dis. 2007 Nov;66 Suppl 3(Suppl 3):iii2-22. doi: 10.1136/ard.2007.081430.
8
Diagnosis, differential diagnosis and treatment of polymyalgia rheumatica.风湿性多肌痛的诊断、鉴别诊断及治疗
Drugs Aging. 2006;23(5):391-402. doi: 10.2165/00002512-200623050-00003.
9
[Modern antirheumatic pharmacotherapy. Low molecular weight substances vs. biologicals].[现代抗风湿药物治疗。低分子量物质与生物制剂]
Internist (Berl). 2005 Dec;46(12):1399-404. doi: 10.1007/s00108-005-1501-y.
10
A disease activity score for polymyalgia rheumatica.风湿性多肌痛的疾病活动评分。
Ann Rheum Dis. 2004 Oct;63(10):1279-83. doi: 10.1136/ard.2003.011379.

本文引用的文献

1
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.英夫利昔单抗治疗活动性强直性脊柱炎：一项随机对照多中心试验。
Lancet. 2002 Apr 6;359(9313):1187-93. doi: 10.1016/s0140-6736(02)08215-6.
2
Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.重组人白细胞介素-1受体拮抗剂阿那白滞素联合甲氨蝶呤治疗类风湿关节炎：一项为期24周的多中心、随机、双盲、安慰剂对照试验的结果。
Arthritis Rheum. 2002 Mar;46(3):614-24. doi: 10.1002/art.10141.
3
Targeting interleukin-1 in the treatment of rheumatoid arthritis.靶向白细胞介素-1治疗类风湿关节炎。
Arthritis Rheum. 2002 Mar;46(3):574-8. doi: 10.1002/art.10168.
4
Remission of Behçet's syndrome with TNFalpha blocking treatment.使用肿瘤坏死因子α阻断治疗使白塞病缓解。
Ann Rheum Dis. 2002 Mar;61(3):283-4. doi: 10.1136/ard.61.3.283-a.
5
Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.抗肿瘤坏死因子α治疗炎性关节炎期间发生的脱髓鞘病变。
Arthritis Rheum. 2001 Dec;44(12):2862-9. doi: 10.1002/1529-0131(200112)44:12<2862::aid-art474>3.0.co;2-w.
6
Infliximab in patients with primary Sjögren's syndrome: a pilot study.英夫利昔单抗治疗原发性干燥综合征患者：一项试点研究。
Arthritis Rheum. 2001 Oct;44(10):2371-5. doi: 10.1002/1529-0131(200110)44:10<2371::aid-art401>3.0.co;2-w.
7
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.与英夫利昔单抗（一种肿瘤坏死因子α中和剂）相关的结核病。
N Engl J Med. 2001 Oct 11;345(15):1098-104. doi: 10.1056/NEJMoa011110.
8
Effect of infliximab on sight-threatening panuveitis in Behçet's disease.英夫利昔单抗对贝赫切特病中威胁视力的全葡萄膜炎的疗效。
Lancet. 2001 Jul 28;358(9278):295-6. doi: 10.1016/s0140-6736(01)05497-6.
9
Evaluation and documentation of rheumatoid arthritis disease status in the clinic: which variables best predict change in therapy.临床中类风湿性关节炎疾病状态的评估与记录：哪些变量最能预测治疗变化。
J Rheumatol. 2001 Jul;28(7):1712-7.
10
Osteopontin: an intrinsic inhibitor of inflammation in cartilage.骨桥蛋白：软骨炎症的内源性抑制剂。
Arthritis Rheum. 2001 Mar;44(3):578-84. doi: 10.1002/1529-0131(200103)44:3<578::AID-ANR106>3.0.CO;2-7.